Sage, Bio­gen tout an­oth­er PhI­II win for de­pres­sion pill, but dura­bil­i­ty con­cerns again cloud the drug's fu­ture

4 years ago
R&D

In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

4 years ago
R&D

With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

4 years ago
R&D

An­tibi­ot­ic re­sis­tance start­up gets $33M from Boehringer, No­vo; Equi­l­li­um bags a tri-specf­ic

4 years ago
News Briefing

Af­ter an about-face on a PhI­II tri­al, FDA sets up an ad­comm to re­view con­tro­ver­sial ALS drug next month

4 years ago
Pharma
FDA+

No­var­tis vet is get­ting an­oth­er shot at mTOR fol­low­ing the im­plo­sion of a longevi­ty pi­o­neer

4 years ago
Startups
Deals

Some genes are too large to fit in­to AAV vec­tors. UCB, No­var­tis back $57M idea to de­liv­er them in parts in­stead

4 years ago
Financing
Startups

Hunt­ing deals on all fronts, Mer­ck en­lists drug dis­cov­ery biotech on search for pro­tein mod­u­la­tors

4 years ago
Deals

Au­dentes’ for­mer CEO launch­es new biotech, with $155M for hives and in­flam­ma­tion

4 years ago
Financing
Startups

A new start­up sets course against a con­stel­la­tion of rare dis­eases with a first shot re­pur­pos­ing the SIRP path­way

4 years ago
Financing
Startups

Mi­rati gets a stan­dard re­view for its 'break­through' KRAS drug. And that is caus­ing some hand wring­ing

4 years ago
Bioregnum
FDA+

Mod­er­na turns to Asia, plots new hires as it pon­ders $35B+ Covid-19 vac­cine wind­fall

4 years ago
Coronavirus

Gilead re­jigs HIV im­munother­a­py pact, grabs a stake in biotech part­ner

4 years ago
Deals

Ben­e­fits of Lil­ly's di­a­betes can­di­date tirzepatide aren't bet­ter than oth­er di­a­betes drugs, says watch­dog ICER

4 years ago
Pharma

Court sides with Te­va over Emer­gent in gener­ic Nar­can suit

4 years ago
Pharma
Manufacturing

Neil Young's Spo­ti­fy protest puts Pfiz­er back in the crosshairs of vac­cine con­spir­a­cy the­o­ries

4 years ago
Pharma

In­dus­try wants new Eu­ro­pean phar­ma makeover to in­crease the con­ti­nen­t's at­trac­tive­ness for R&D

4 years ago
Pharma

Mod­er­na’s once high-fly­ing stock buck­les un­der the weight of a biotech rout. Is it cheap yet?

4 years ago
Bioregnum
Pharma

Pad­cev gets a shot at an­oth­er in­di­ca­tion — for in­va­sive blad­der can­cer — thanks to ini­tial da­ta read­out

4 years ago
R&D
Pharma

As­traZeneca/Mer­ck come out of AS­CO GU with a big win over J&J in bat­tle over prostate can­cer fran­chis­es

4 years ago
R&D

Catal­ent ex­pands deep-freeze op­er­a­tions in Chi­nese free trade zone

4 years ago
Manufacturing

In a nail-biter, Rob Califf gets a sec­ond shot at FDA com­mis­sion­er with Sen­ate con­fir­ma­tion

4 years ago
People
FDA+

With FDA nods and third-shot OKs, Mod­er­na and Pfiz­er boost vac­cine ads – and boost­er mes­sages

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Su­per Bowl scores last minute ad from di­ag­nos­tic; BBC spot­lights As­traZeneca vac­cine

4 years ago
Pharma
Marketing
First page Previous page 573574575576577578579 Next page Last page
A service from the Financial Times